voxelotor,crizanlizumab,hydroxyurea
global blood therapeutics,novartis
['crizanlizumab', 'voxelotor', 'hydroxyurea']
the increased use of disease modifying treatments was driven by the recent approvals of crizanlizumab and voxelotor, use of endari has remained flat. #ash22 
Psychologist, epidemiologist, helping bridge #healthdisparities through innovative #mhealth, increasing awareness about #sicklecell, engaging the community.